CV NEWS FEED // Authors of a peer-reviewed study published this week are calling for further investigation into the adverse effects of the COVID-19 shot after finding shocking rates of COVID-19 shot-induced myocarditis, especially in males between the ages of 0 and 30.
On January 27, peer-reviewed journal Therapeutic Advances in Drug Safety published the study conducted by Jessica Rose, Nicholas Hulscher, and Peter McCullough titled “Determinants of COVID-19 vaccine-induced myocarditis.”
Myocarditis is a heart-inflammatory health condition that puts its sufferers at risk of “chest pain, heart failure, or sudden death,” the authors noted.
After the distribution of the COVID-19 shot through pharmaceutical companies such as Pfizer and Moderna, “millions of individuals have reported adverse events (AEs) using the vaccine adverse events reports system (VAERS),” the authors wrote:
We used VAERS data to examine the frequency of reporting myocarditis since the beginning of the mass vaccination campaign and compared this with historical values in VAERS and COVID-19 vaccine administration data from the Our World in Data database. We examined myocarditis reports in VAERS in the context of sex, age, and dose.
The authors wrote that their study’s findings indicated an “imperative” need to launch “further investigation into the underlying mechanisms of COVID-19 vaccine-induced myocarditis.”
“COVID-19 vaccination is strongly associated with a serious adverse safety signal of myocarditis, particularly in children and young adults resulting in hospitalization and death,” the authors wrote:
We found the number of myocarditis reports in VAERS after COVID-19 vaccination in 2021 was 223 times higher than the average of all vaccines combined for the past 30 years.
This represented a 2500% increase in the absolute number of reports in the first year of the campaign when comparing historical values prior to 2021.
“As of 11 August 2023, a total of 3078 reports of COVID-19 vaccine-induced myocarditis (0.3% of all AEs) have been reported to VAERS,” the authors wrote. “Of these reports, 76% resulted in emergency care and hospitalization, while 3% suffered death. Among all reports, 69% of the myocarditis occurred in men.”
The study found that the risk of myocarditis was “more likely following a second dose of vaccine. Furthermore, individuals under the age of 30 were more prone to acquire myocarditis from COVID-19 vaccination compared to those aged 30 and above.”
The authors noted the limitations of their study and warned that it is likely the COVID-19 vaccine-induced myocarditis “cases reported [to VAERS] thus far are not rare, but rather, just the tip of the iceberg.”
The long-term effects of the COVID-19 shot are still unknown, especially because of its unprecedented use of spike-protein technology, the authors highlighted. Yet, the Food and Drug Administration approved the shot at an expedited rate during the COVID-19 health crisis.
“The typical timeline is up to 10 years for a proper safety and efficacy assessment of a novel genetic product,” the authors wrote:
The COVID-19 vaccines were rushed through phase I–III trials in about 10 months with the Operation Warp Speed initiative.
Safety signals emerging from VAERS were apparent in January of 2021. Reports of death after product administration should prompt market withdrawal.
Going forward, the authors highlighted the “need to study more about how the COVID-19 vaccine might cause heart inflammation to find ways to prevent it and make sure the vaccine is safe for continued use in all age groups.”
“We found a very strong safety signal for COVID-19 vaccine-induced myocarditis, particularly in children and young adults, that resulted in hospitalization and death,” the authors concluded:
COVID-19 vaccines induce an uncontrolled expression of potentially lethal SARS-CoV-2 spike protein within human cells, have a close temporal relationship of events, and are internally and externally consistent with emerging sources of clinical and peer-reviewed data supporting the conclusion that COVID-19 vaccines are deterministic for myocarditis, including fatal cases.
Further investigation into the underlying mechanisms of COVID-19 vaccine-induced myocarditis is imperative to create effective mitigation strategies and ensure the safety of COVID-19 vaccination programs across populations.